Small intestinal bacterial overgrowth and intestinal methanogen overgrowth in gastrointestinal malignancies.

IF 2.9 Q2 ONCOLOGY
Wspolczesna Onkologia-Contemporary Oncology Pub Date : 2025-01-01 Epub Date: 2025-03-18 DOI:10.5114/wo.2025.148643
Aleksandra Mechlińska, Katarzyna Frąckiewicz, Katarzyna Gładyś-Cieszyńska, Dagmara Buczek, Rafał Dziadziuszko
{"title":"Small intestinal bacterial overgrowth and intestinal methanogen overgrowth in gastrointestinal malignancies.","authors":"Aleksandra Mechlińska, Katarzyna Frąckiewicz, Katarzyna Gładyś-Cieszyńska, Dagmara Buczek, Rafał Dziadziuszko","doi":"10.5114/wo.2025.148643","DOIUrl":null,"url":null,"abstract":"<p><p>Small intestinal bacterial overgrowth (SIBO) is defined by an abnormal proliferation of colon-specific bacteria in the small intestine, whereas intestinal methanogen overgrowth (IMO) manifests with an increase of methane-producing archaea, specifically Methanobrevibacter smithii. Both conditions can disrupt gastrointestinal motility and manifest with various clinical symptoms. Small intestinal bacterial overgrowth appears to increase the risk of malnutrition and negatively affect malabsorption of essential nutrients such as vitamin B<sub>12</sub> and fat-soluble vitamins. This concern is particularly relevant for cancer patients as malnutrition can adversely affect treatment outcomes and mortality rates. Small intestinal bacterial overgrowth prevalence is 2.5-22% in the general population, with significantly higher rates observed in cancer patients, depending on a study, 65% of gastric and colorectal cancer patients, 63.3% of pancreatic cancer patients compared to 13.3% in healthy controls. Gastrointestinal complications, particularly in cases of gastrointestinal cancers, can arise from both the disease itself and its treatment. Managing symptoms becomes more challenging when SIBO occurs as its symptoms are often ambiguous and overlap with those of other conditions. This review summarizes the current state of knowledge on SIBO and IMO in gastrointestinal cancers. Current knowledge on SIBO and IMO, particularly in gastrointestinal cancer, is limited by the lack of validated diagnostic standards, evidence-based nutritional guidelines, and a focus on symptom control rather than underlying mechanisms. There is a need for research on recurrence despite treatment, as well as studies specifically targeting SIBO and IMO in cancer rather than as comorbidities. Future efforts should prioritize developing reliable diagnostics, understanding recurrence mechanisms, and exploring personalized therapies and nutritional interventions.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":"29 1","pages":"11-21"},"PeriodicalIF":2.9000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12051882/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Wspolczesna Onkologia-Contemporary Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/wo.2025.148643","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/18 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Small intestinal bacterial overgrowth (SIBO) is defined by an abnormal proliferation of colon-specific bacteria in the small intestine, whereas intestinal methanogen overgrowth (IMO) manifests with an increase of methane-producing archaea, specifically Methanobrevibacter smithii. Both conditions can disrupt gastrointestinal motility and manifest with various clinical symptoms. Small intestinal bacterial overgrowth appears to increase the risk of malnutrition and negatively affect malabsorption of essential nutrients such as vitamin B12 and fat-soluble vitamins. This concern is particularly relevant for cancer patients as malnutrition can adversely affect treatment outcomes and mortality rates. Small intestinal bacterial overgrowth prevalence is 2.5-22% in the general population, with significantly higher rates observed in cancer patients, depending on a study, 65% of gastric and colorectal cancer patients, 63.3% of pancreatic cancer patients compared to 13.3% in healthy controls. Gastrointestinal complications, particularly in cases of gastrointestinal cancers, can arise from both the disease itself and its treatment. Managing symptoms becomes more challenging when SIBO occurs as its symptoms are often ambiguous and overlap with those of other conditions. This review summarizes the current state of knowledge on SIBO and IMO in gastrointestinal cancers. Current knowledge on SIBO and IMO, particularly in gastrointestinal cancer, is limited by the lack of validated diagnostic standards, evidence-based nutritional guidelines, and a focus on symptom control rather than underlying mechanisms. There is a need for research on recurrence despite treatment, as well as studies specifically targeting SIBO and IMO in cancer rather than as comorbidities. Future efforts should prioritize developing reliable diagnostics, understanding recurrence mechanisms, and exploring personalized therapies and nutritional interventions.

胃肠道恶性肿瘤中小肠细菌过度生长和肠道产甲烷菌过度生长。
小肠细菌过度生长(SIBO)是指小肠中结肠特异性细菌的异常增殖,而肠道产甲烷菌过度生长(IMO)则表现为产甲烷古菌的增加,特别是史密斯甲烷预防杆菌。这两种情况均可扰乱胃肠运动,并表现为各种临床症状。小肠细菌过度生长似乎会增加营养不良的风险,并对维生素B12和脂溶性维生素等必需营养素的吸收不良产生负面影响。这一担忧与癌症患者尤其相关,因为营养不良会对治疗结果和死亡率产生不利影响。在一般人群中,小肠细菌过度生长的患病率为2.5-22%,在癌症患者中观察到的比例明显更高,根据一项研究,65%的胃癌和结直肠癌患者,63.3%的胰腺癌患者,而健康对照组为13.3%。胃肠道并发症,特别是胃肠道癌症,可由疾病本身及其治疗引起。当SIBO发生时,管理症状变得更具挑战性,因为它的症状通常是模糊的,并且与其他疾病的症状重叠。本文综述了SIBO和IMO在胃肠道肿瘤中的研究现状。由于缺乏有效的诊断标准、循证营养指南,以及关注症状控制而非潜在机制,目前关于SIBO和IMO的知识,特别是在胃肠道癌症方面的知识有限。有必要研究治疗后的复发,以及专门针对SIBO和IMO在癌症中的研究,而不是作为合并症。未来的工作应优先发展可靠的诊断,了解复发机制,探索个性化治疗和营养干预。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.10
自引率
0.00%
发文量
22
审稿时长
4-8 weeks
期刊介绍: Contemporary Oncology is a journal aimed at oncologists, oncological surgeons, hematologists, radiologists, pathologists, radiotherapists, palliative care specialists, psychologists, nutritionists, and representatives of any other professions, whose interests are related to cancer. Manuscripts devoted to basic research in the field of oncology are also welcomed.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信